{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:45:19Z","timestamp":1790196319567,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Umea University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Through this meta-analysis, we aim to provide an overview and statistical synthesis of the prevalence of MetS and its components in psoriatic arthritis (PsA) compared to the general populations, patients with cutaneous psoriasis (PsO), and patients with other inflammatory arthropathies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A search was conducted in Ovid Medline, Web of Science, and Scopus up to February 2024. Original articles investigating the prevalence of MetS in PsA in adults compared to one or more comparison populations were included. Bias risk was assessed by means of a funnel plot. The data was analyzed by means of a random effects model and presented in forest plots.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 1526 articles in the original search, 20 relevant were identified. Meta-analyses showed an increased prevalence of MetS in PsA compared to the general population, rheumatoid arthritis (RA), and ankylosing spondylitis (AS) (LogOR 0.93, 0.63, and 1.04, respectively). Meta-analysis showed no difference in the prevalence of MetS in PsA compared to PsO (LogOR 0.15,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      0.63). Meta-analysis of the prevalence of the different components of MetS in PsA compared to RA showed an increased prevalence of central obesity, hypertriglyceridemia, impaired glucose tolerance, and diabetes mellitus.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      PsA was associated with an increased risk of MetS compared to the risk in the general population, in RA and in AS, respectively. This emphasizes the importance of screening for and taking necessary measures to prevent MetS in patients with PsA.\n                      <jats:table-wrap>\n                        <jats:table>\n                          <jats:tbody>\n                            <jats:tr>\n                              <jats:td align=\"left\" colspan=\"2\">\n                                <jats:bold>Key Points<\/jats:bold>\n                                \u2022\n                                <jats:italic>Patients with PsA have an increased risk of MetS compared to the general population as well as patients with RA or AS<\/jats:italic>\n                                .\u2022\u00a0\n                                <jats:italic>According to this meta-analysis, the risk of MetS is the same in patients with PsA as in patients with PsO<\/jats:italic>\n                              <\/jats:td>\n                            <\/jats:tr>\n                          <\/jats:tbody>\n                        <\/jats:table>\n                      <\/jats:table-wrap>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10067-025-07637-z","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T20:43:00Z","timestamp":1755549780000},"page":"3787-3799","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Prevalence of metabolic syndrome and its components in psoriatic arthritis compared with general population, cutaneous psoriasis, and other inflammatory arthropathies: a meta-analysis"],"prefix":"10.1007","volume":"44","author":[{"given":"Sara","family":"Andreasson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7436-7900","authenticated-orcid":false,"given":"Anna","family":"S\u00f6dergren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"key":"7637_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2021.101694","author":"C Stober","year":"2021","unstructured":"Stober C (2021) Pathogenesis of psoriatic arthritis. Best Pract Res Clin Rheumatol. https:\/\/doi.org\/10.1016\/j.berh.2021.101694","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"7637_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2021.101670","author":"M Kishimoto","year":"2021","unstructured":"Kishimoto M, Deshpande GA, Fukuoka K, Kawakami T, Ikegaya N, Kawashima S et al (2021) Clinical features of psoriatic arthritis. Best Pract Res Clin Rheumatol. https:\/\/doi.org\/10.1016\/j.berh.2021.101670","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"7","key":"7637_CR3","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.3899\/jrheum.090822","volume":"37","author":"AM Tobin","year":"2010","unstructured":"Tobin AM, Veale DJ, Fitzgerald O, Rogers S, Collins P, O\u2019Shea D et al (2010) Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. J Rheumatol 37(7):1386\u20131394","journal-title":"J Rheumatol"},{"issue":"7","key":"7637_CR4","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/acr.22536","volume":"67","author":"FC Ernste","year":"2015","unstructured":"Ernste FC, Sanchez-Menendez M, Wilton KM, Crowson CS, Matteson EL, Maradit Kremers H (2015) Cardiovascular risk profile at the onset of psoriatic arthritis: a population-based cohort study. Arthritis Care Res (Hoboken) 67(7):1015\u20131021","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"7637_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/acr.22926","volume":"69","author":"A Polachek","year":"2017","unstructured":"Polachek A, Touma Z, Anderson M, Eder L (2017) Risk of cardiovascular morbidity in patients with psoriatic arthritis: a meta-analysis of observational studies. Arthritis Care Res (Hoboken) 69(1):67\u201374","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"7637_CR6","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/art.22884","volume":"57","author":"C Gonzalez-Juanatey","year":"2007","unstructured":"Gonzalez-Juanatey C, Llorca J, Amigo-Diaz E, Dierssen T, Martin J, Gonzalez-Gay MA (2007) High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 57(6):1074\u20131080","journal-title":"Arthritis Rheum"},{"issue":"5","key":"7637_CR7","first-page":"877","volume":"35","author":"L Eder","year":"2008","unstructured":"Eder L, Zisman D, Barzilai M, Laor A, Rahat M, Rozenbaum M et al (2008) Subclinical atherosclerosis in psoriatic arthritis: a case-control study. J Rheumatol 35(5):877\u2013882","journal-title":"J Rheumatol"},{"key":"7637_CR8","doi-asserted-by":"crossref","unstructured":"Adeodato Ramos LM, Gomes KWP, de Saboia Mont\u2019Alverne AR, Braga MV, Costa Vasconcelos AH, Rodrigues CEM. High prevalence of metabolic syndrome in patients with psoriatic arthritis from Northeastern Brazil: association with traditional cardiovascular risk factors and biologic disease-modifying antirheumatic drugs. J Clin Rheumatol. 2021;27(6S):S186-S92.","DOI":"10.1097\/RHU.0000000000001631"},{"issue":"2","key":"7637_CR9","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/BOR.0000000000000152","volume":"27","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Schwartzman S, Husni ME (2015) Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol 27(2):118\u2013126","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"7637_CR10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1177\/1759720X15591801","volume":"7","author":"L Eder","year":"2015","unstructured":"Eder L, Gladman DD (2015) Atherosclerosis in psoriatic disease: latest evidence and clinical implications. Ther Adv Musculoskelet Dis 7(5):187\u2013195","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"5\u20136","key":"7637_CR11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1242\/dmm.001180","volume":"2","author":"PL Huang","year":"2009","unstructured":"Huang PL (2009) A comprehensive definition for metabolic syndrome. Dis Model Mech 2(5\u20136):231\u2013237","journal-title":"Dis Model Mech"},{"issue":"5","key":"7637_CR12","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.2337\/dc06-2484","volume":"30","author":"JB Meigs","year":"2007","unstructured":"Meigs JB, Rutter MK, Sullivan LM, Fox CS, D\u2019Agostino RB Sr, Wilson PW (2007) Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care 30(5):1219\u20131225","journal-title":"Diabetes Care"},{"issue":"2","key":"7637_CR13","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3899\/jrheum.150757","volume":"43","author":"M Haroon","year":"2016","unstructured":"Haroon M, Chaudhry RAB, Fitzgerald O (2016) Higher prevalence of metabolic syndrome in patients with psoriatic arthritis: a comparison with a control group of noninflammatory rheumatologic conditions. J Rheumatol 43(2):463\u2013464","journal-title":"J Rheumatol"},{"issue":"1","key":"7637_CR14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.5152\/eurjrheum.2017.16052","volume":"4","author":"SG \u00d6zkan","year":"2017","unstructured":"\u00d6zkan SG, Yazisiz H, Behl\u00fcl A, G\u00f6kbelen YA, Borlu F, Yazisiz V (2017) Prevalence of metabolic syndrome and degree of cardiovascular disease risk in patients with psoriatic arthritis. Eur J Rheumatol 4(1):40\u201345","journal-title":"Eur J Rheumatol"},{"key":"7637_CR15","doi-asserted-by":"crossref","unstructured":"Adeodato Ramos LM, Gomes KWP, De Saboia Mont\u2019alverne AR, Braga MV, Costa Vasconcelos AH, Rodrigues CEM. High prevalence of metabolic syndrome in patients with psoriatic arthritis from Northeastern Brazil: association with traditional cardiovascular risk factors and biologic disease-modifying antirheumatic drugs. Journal of Clinical Rheumatology. 2021;27:S186-S92.","DOI":"10.1097\/RHU.0000000000001631"},{"issue":"6","key":"7637_CR16","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/RHU.0000000000000721","volume":"24","author":"J Feld","year":"2018","unstructured":"Feld J, Nissan S, Eder L, Rahat MA, Elias M, Rimar D et al (2018) Increased prevalence of metabolic syndrome and adipocytokine levels in a psoriatic arthritis cohort. JCR J Clin Rheumatol 24(6):302\u2013307","journal-title":"JCR J Clin Rheumatol"},{"issue":"2","key":"7637_CR17","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/acr.20363","volume":"63","author":"CC Mok","year":"2011","unstructured":"Mok CC, Ko GT, Ho LY, Yu KL, Chan PT, To CH (2011) Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken) 63(2):195\u2013202","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"7637_CR18","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1136\/annrheumdis-2012-202325","volume":"72","author":"L Eder","year":"2013","unstructured":"Eder L, Jayakar J, Pollock R, Pellett F, Thavaneswaran A, Chandran V et al (2013) Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. Ann Rheum Dis 72(12):1956\u20131961","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"7637_CR19","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/acr.22185","volume":"66","author":"M Labitigan","year":"2014","unstructured":"Labitigan M, Bahce-Altuntas A, Kremer JM, Reed G, Greenberg JD, Jordan N et al (2014) Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis. Arthritis Care Res (Hoboken) 66(4):600\u2013607","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"7637_CR20","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/rheumatology\/ken090","volume":"47","author":"LS Tam","year":"2008","unstructured":"Tam LS, Tomlinson B, Chu TTW, Li M, Leung YY, Kwok LW et al (2008) Cardiovascular risk profile of patients with psoriatic arthritis compared to controls - the role of inflammation. Rheumatology (Oxford) 47(5):718\u2013723","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"7637_CR21","first-page":"43","volume":"12","author":"S Pehlevan","year":"2014","unstructured":"Pehlevan S, Yetkin DO, Bahadir C, Goktay F, Pehlevan Y, Kayatas K et al (2014) Increased prevalence of metabolic syndrome in patients with psoriatic arthritis. Metab 12(1):43\u201348","journal-title":"Metab"},{"key":"7637_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12155031","author":"F Atzeni","year":"2023","unstructured":"Atzeni F, La Corte L, Cirillo M, Giallanza M, Galloway J, Rodr\u00edguez-Carrio J (2023) Metabolic syndrome and its components have a different presentation and impact as cardiovascular risk factors in psoriatic and rheumatoid arthritis. J Clin Med. https:\/\/doi.org\/10.3390\/jcm12155031","journal-title":"J Clin Med"},{"issue":"4","key":"7637_CR23","first-page":"322","volume":"44","author":"S Azevedo","year":"2019","unstructured":"Azevedo S, Santos-Faria D, Leite Silva J, Ramos Rodrigues J, Sousa Neves J, Peixoto D et al (2019) Obesity, metabolic syndrome and other comorbidities in rheumatoid arthritis and psoriatic arthritis: influence on disease activity and quality of life. Acta Reumatol 44(4):322\u2013324","journal-title":"Acta Reumatol"},{"issue":"4","key":"7637_CR24","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/jdv.12071","volume":"28","author":"J Bostoen","year":"2014","unstructured":"Bostoen J, Van Praet L, Brochez L, Mielants H, Lambert J (2014) A cross-sectional study on the prevalence of metabolic syndrome in psoriasis compared to psoriatic arthritis. J Eur Acad Dermatol Venereol 28(4):507\u2013511","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"7637_CR25","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s11739-020-02520-y","volume":"16","author":"G Cioffi","year":"2021","unstructured":"Cioffi G, Viapiana O, Tarantini L, Orsolini G, Idolazzi L, Sonographer FO et al (2021) Clinical profile and outcome of patients with chronic inflammatory arthritis and metabolic syndrome. Intern Emerg Med 16(4):863\u2013874","journal-title":"Intern Emerg Med"},{"issue":"6","key":"7637_CR26","doi-asserted-by":"publisher","first-page":"e14378","DOI":"10.1111\/dth.14378","volume":"33","author":"D Dagdelen","year":"2020","unstructured":"Dagdelen D, Karadag AS, Kasapoglu E, Wang JV, Erman H (2020) Correlation of metabolic syndrome with serum omentin-1 and visfatin levels and disease severity in psoriasis and psoriatic arthritis. Dermatol Ther 33(6):e14378","journal-title":"Dermatol Ther"},{"issue":"8","key":"7637_CR27","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1002\/art.40499","volume":"70","author":"ME Husni","year":"2018","unstructured":"Husni ME, Wilson Tang WH, Lucke M, Chandrasekharan UM, Brennan DM, Hazen SL (2018) Correlation of high-density lipoprotein-associated paraoxonase 1 activity with systemic inflammation, disease activity, and cardiovascular risk factors in psoriatic disease. Arthritis Rheumatol 70(8):1240\u20131250","journal-title":"Arthritis Rheumatol"},{"key":"7637_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.993363","author":"G Larid","year":"2022","unstructured":"Larid G, Delwail A, Dalle T, Vasseur P, Silvain C, Jegou JF et al (2022) Ex vivo cytokine production in psoriatic disease: towards specific signatures in cutaneous psoriasis and peripheral psoriatic arthritis. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.993363","journal-title":"Front Immunol"},{"issue":"1","key":"7637_CR29","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40744-022-00502-4","volume":"10","author":"B Li","year":"2023","unstructured":"Li B, Huang H, Zhao J, Deng X, Zhang Z (2023) Discrepancy in metabolic syndrome between psoriatic arthritis and rheumatoid arthritis: a direct comparison of two cohorts in one center. Rheumatol Ther 10(1):135\u2013148","journal-title":"Rheumatol Ther"},{"issue":"1","key":"7637_CR30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/acr.22144","volume":"66","author":"YC Lin","year":"2014","unstructured":"Lin YC, Dalal D, Churton S, Brennan DM, Korman NJ, Kim ES et al (2014) Relationship between metabolic syndrome and carotid intima\u2010media thickness: cross\u2010sectional comparison between psoriasis and psoriatic arthritis. Arthritis Care Res 66(1):97\u2013103","journal-title":"Arthritis Care Res"},{"key":"7637_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-021-04222-8","author":"C Petcharat","year":"2021","unstructured":"Petcharat C, Srinonprasert V, Chiowchanwisawakit P (2021) Association between syndesmophyte and metabolic syndrome in patients with psoriatic arthritis or ankylosing spondylitis: a cross-sectional study. BMC Musculoskelet Disord. https:\/\/doi.org\/10.1186\/s12891-021-04222-8","journal-title":"BMC Musculoskelet Disord"},{"issue":"4","key":"7637_CR32","doi-asserted-by":"publisher","first-page":"174","DOI":"10.5152\/eurjrheum.2019.19029","volume":"6","author":"\u00d6 \u00d6zkul","year":"2019","unstructured":"\u00d6zkul \u00d6, Yazici A, Akt\u00fcrk SS, Karadag DT, Isik OO, Tekeoglu S et al (2019) Are there any differences among psoriasis, psoriatic arthritis and rheumatoid arthritis in terms of metabolic syndrome and cardiovascular risk factors? Eur J Rheumatol 6(4):174\u2013178","journal-title":"Eur J Rheumatol"},{"issue":"2","key":"7637_CR33","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3899\/jrheum.141359","volume":"43","author":"N Haque","year":"2016","unstructured":"Haque N, Lories RJ, de Vlam K (2016) Comorbidities associated with psoriatic arthritis compared with non-psoriatic spondyloarthritis: a cross-sectional study. J Rheumatol 43(2):376\u2013382","journal-title":"J Rheumatol"},{"issue":"4","key":"7637_CR34","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1089\/met.2009.0124","volume":"8","author":"SK Raychaudhuri","year":"2010","unstructured":"Raychaudhuri SK, Chatterjee S, Nguyen C, Kaur M, Jialal I, Raychaudhuri SP (2010) Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord 8(4):331\u2013334","journal-title":"Metab Syndr Relat Disord"},{"issue":"6","key":"7637_CR35","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1093\/rheumatology\/keaa720","volume":"60","author":"E Toussirot","year":"2021","unstructured":"Toussirot E, Aubin F, Desmarets M, Wendling D, Auge B, Gillard J et al (2021) Visceral adiposity in patients with psoriatic arthritis and psoriasis alone and its relationship with metabolic and cardiovascular risk. Rheumatology (Oxford) 60(6):2816\u20132825","journal-title":"Rheumatology (Oxford)"},{"issue":"16","key":"7637_CR36","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"KG Alberti","year":"2009","unstructured":"Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity et al (2009) Harmonizing the metabolic syndrome. Circulation 120(16):1640\u20131645","journal-title":"Circulation"},{"issue":"9","key":"7637_CR37","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1111\/1756-185X.14147","volume":"24","author":"A Loganathan","year":"2021","unstructured":"Loganathan A, Kamalaraj N, El-Haddad C, Pile K (2021) Systematic review and meta-analysis on prevalence of metabolic syndrome in psoriatic arthritis, rheumatoid arthritis and psoriasis. Int J Rheum Dis 24(9):1112\u20131120","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"7637_CR38","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3899\/jrheum.111244","volume":"39","author":"SP Raychaudhuri","year":"2012","unstructured":"Raychaudhuri SP (2012) Comorbidities of psoriatic arthritis \u2013 metabolic syndrome and prevention: a report from the GRAPPA 2010 annual meeting. J Rheumatol 39(2):437\u2013440","journal-title":"J Rheumatol"},{"key":"7637_CR39","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2147\/OARRR.S347797","volume":"14","author":"R Aljohani","year":"2022","unstructured":"Aljohani R (2022) Metabolic syndrome and its components in psoriatic arthritis. Open Access Rheumatol 14:7\u201316","journal-title":"Open Access Rheumatol"},{"issue":"1","key":"7637_CR40","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1093\/rheumatology\/kes242","volume":"52","author":"A Russolillo","year":"2013","unstructured":"Russolillo A, Iervolino S, Peluso R, Lupoli R, Di Minno A, Pappone N et al (2013) Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management. Rheumatology (Oxford) 52(1):62\u201367","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"7637_CR41","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2217\/ijr.15.33","volume":"10","author":"J Hong","year":"2015","unstructured":"Hong J, Maron DJ, Shirai T, Weyand CM (2015) Accelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditions. Int J Clin Rheumatol 10(5):365\u2013381","journal-title":"Int J Clin Rheumatol"},{"issue":"7","key":"7637_CR42","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/acr.22536","volume":"67","author":"FC Ernste","year":"2015","unstructured":"Ernste FC, S\u00e1nchez-Men\u00e9ndez M, Wilton KM, Crowson CS, Matteson EL, Maradit Kremers H (2015) Cardiovascular risk profile at the onset of psoriatic arthritis: a population-based cohort study. Arthritis Care Res (Hoboken) 67(7):1015\u20131021","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"7637_CR43","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1136\/annrheumdis-2012-201299","volume":"71","author":"TJ Love","year":"2012","unstructured":"Love TJ, Zhu Y, Zhang Y, Wall-Burns L, Ogdie A, Gelfand JM et al (2012) Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis 71(8):1273\u20131277","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"7637_CR44","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s10067-013-2369-1","volume":"33","author":"L Costa","year":"2014","unstructured":"Costa L, Caso F, Atteno M, Del Puente A, Darda MA, Caso P et al (2014) Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol 33(6):833\u2013839","journal-title":"Clin Rheumatol"},{"issue":"6","key":"7637_CR45","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/jdv.12768","volume":"29","author":"O Ahlehoff","year":"2015","unstructured":"Ahlehoff O, Skov L, Gislason G, Gniadecki R, Iversen L, Bryld LE et al (2015) Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. J Eur Acad Dermatol Venereol 29(6):1128\u20131134","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"7637_CR46","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3899\/jrheum.171034","volume":"46","author":"A Ogdie","year":"2019","unstructured":"Ogdie A, Palmer JL, Greenberg J, Curtis JR, Harrold LR, Solomon DH et al (2019) Predictors of achieving remission among patients with psoriatic arthritis initiating a tumor necrosis factor inhibitor. J Rheumatol 46(5):475\u2013482","journal-title":"J Rheumatol"},{"issue":"6","key":"7637_CR47","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H et al (2024) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis 83(6):706\u2013719","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"7637_CR48","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/art.22447","volume":"56","author":"N Sattar","year":"2007","unstructured":"Sattar N, Crompton P, Cherry L, Kane D, Lowe G, McInnes IB (2007) Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 56(3):831\u20139","journal-title":"Arthritis Rheum"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07637-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07637-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07637-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:12:56Z","timestamp":1760364776000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07637-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["7637"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07637-z","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]},"assertion":[{"value":"19 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}